Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01854918 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,681
- Enrollment target
NCT01854918 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 3,681 participants.
The verdict
NCT01854918, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,681 participants
- Enrollment target
Study Summary
This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
Interventions
- DRUG Standard of Care
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,681 participants |
| Start Date | 2013-04-23 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01854918
The ClinicalTrials.gov registry entry for NCT01854918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,681 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01854918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01854918 about?
NCT01854918 is a clinical study titled "Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia". This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.
What is the current status of trial NCT01854918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,681 participants. The study started on 2013-04-23. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT01854918?
The interventions under investigation include: Standard of Care (DRUG), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01854918?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.